TP53 and breast carcinoma: MAP was found to be methodologically robust when utilized i) to detect EGFR mutations in lung tissue; ii) to detect p53 breast cancer signatures in plasma and the cellular compartments of blood; or iii) to screen for mosaicism for common EGFR mutations in a large population.